1. New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors.
- Author
-
Salgin-Goksen U, Telli G, Erikci A, Dedecengiz E, Tel BC, Kaynak FB, Yelekci K, Ucar G, and Gokhan-Kelekci N
- Subjects
- Animals, Antidepressive Agents chemical synthesis, Antidepressive Agents metabolism, Antidepressive Agents pharmacokinetics, Hep G2 Cells, Humans, Hydrazones chemical synthesis, Hydrazones metabolism, Hydrazones pharmacokinetics, Mice, Molecular Docking Simulation, Molecular Structure, Monoamine Oxidase metabolism, Monoamine Oxidase Inhibitors chemical synthesis, Monoamine Oxidase Inhibitors metabolism, Monoamine Oxidase Inhibitors pharmacokinetics, Protein Binding, Pyrazoles chemical synthesis, Pyrazoles metabolism, Pyrazoles pharmacokinetics, Structure-Activity Relationship, Antidepressive Agents therapeutic use, Depression drug therapy, Hydrazones therapeutic use, Monoamine Oxidase Inhibitors therapeutic use, Pyrazoles therapeutic use
- Abstract
Thirty compounds having 1-[2-(5-substituted-2-benzoxazolinone-3-yl) acetyl]-3,5-disubstitutedphenyl-2-pyrazoline structure and nine compounds having N '-(1,3-disubstitutedphenylallylidene)-2-(5-substituted-2-benzoxazolinone-3-yl)acetohydrazide skeleton were synthesized and evaluated as monoamine oxidase (MAO) inhibitors. All of the compounds exhibited selective MAO-A inhibitor activity in the nanomolar or low micromolar range. The results of the molecular docking for hydrazone derivatives supported the in vitro results. Five compounds, 6 (0.008 μM, Selectivity Index (SI): 9.70 × 10
-4 ), 7 (0.009 μM, SI: 4.55 × 10-5 ), 14 (0.001 μM, SI: 8.00 × 10-4 ), 21 (0.009 μM, SI: 1.37 × 10-5 ), and 42 (0.010 μM, SI: 5.40 × 10-6 ), exhibiting the highest inhibition and selectivity toward hMAO-A and nontoxic to hepatocytes were assessed for antidepressant activity as acute and subchronic in mice. All of these five compounds showed significant antidepressant activity with subchronic administration consistent with the increase in the brain serotonin levels and the compounds crossed the blood-brain barrier according to parallel artificial membrane permeation assay. Compounds 14, 21 , and 42 exhibited an ex vivo MAO-A profile, which is highly consistent with the in vitro data.- Published
- 2021
- Full Text
- View/download PDF